Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Catalyst Pharmaceuticals (CPRX) FCF Margin: 2011-2025

Historic FCF Margin for Catalyst Pharmaceuticals (CPRX) over the last 7 years, with Sep 2025 value amounting to 21.86%.

  • Catalyst Pharmaceuticals' FCF Margin fell 3456.00% to 21.86% in Q3 2025 from the same period last year, while for Sep 2025 it was 40.56%, marking a year-over-year decrease of 808.00%. This contributed to the annual value of 48.65% for FY2024, which is 1265.00% up from last year.
  • As of Q3 2025, Catalyst Pharmaceuticals' FCF Margin stood at 21.86%, which was down 55.05% from 48.63% recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' FCF Margin registered a high of 72.15% during Q3 2022, and its lowest value of 9.61% during Q1 2021.
  • Over the past 3 years, Catalyst Pharmaceuticals' median FCF Margin value was 43.88% (recorded in 2023), while the average stood at 40.26%.
  • Its FCF Margin has fluctuated over the past 5 years, first spiked by 2,137bps in 2024, then plummeted by 3,456bps in 2025.
  • Quarterly analysis of 5 years shows Catalyst Pharmaceuticals' FCF Margin stood at 49.95% in 2021, then surged by 1,601bps to 65.96% in 2022, then crashed by 1,572bps to 50.25% in 2023, then slumped by 33bps to 49.91% in 2024, then slumped by 3,456bps to 21.86% in 2025.
  • Its FCF Margin was 21.86% in Q3 2025, compared to 48.63% in Q2 2025 and 42.46% in Q1 2025.